Drug updated on 3/28/2024

Dosage FormExtended-release capsule (oral; 100 mg, 150 mg, 200 mg)
Drug ClassSelective norepinephrine reuptake inhibitors
Ongoing and
Completed Studies


  • For the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older.

This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Viloxazine (Qelbree) is a medication approved for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 years and older.
  • A meta-analysis found that viloxazine was significantly superior to placebo in managing ADHD, with more patients showing a 50% reduction in ADHD-Rating Scale-5 scores and improved CGI-I scale results compared to those on placebo.
  • However, adverse events were reported significantly more frequently among viloxazine users than among those taking placebos; these included somnolence as well as serious adverse events (SAEs), although the incidence of SAEs was not statistically significant.
  • The information above comes from two systematic reviews/meta-analyses focusing on randomized clinical trials involving viloxazine's use for treating ADHD.
  • Another review highlighted several novel non-stimulant medications being developed for treating ADHD, including viloxazine; while it suggested these new drugs may offer comparable or better tolerability than stimulants, they are unlikely to show greater efficacy at group level.
  • This same review also proposed that some of these new agents could advance pharmacotherapy by targeting etiopathophysiological disruptions specific to certain subgroups of patients with ADHD - moving towards a 'precision medicine' approach rather than 'one size fits all'.

Product Monograph / Prescribing Information

Document TitleYearSource
Qelbree (viloxazine) Prescribing Information.2022Supernus Pharmaceuticals, Inc. Rockville, MD

Systematic Reviews / Meta-Analyses